medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2009, Número 590

<< Anterior Siguiente >>

Rev Med Cos Cen 2009; 66 (590)


Aspirina vs. Clopidogrel en la prevención secunadaris de cardiopatía isquémica

Holtermann H, Podetti C

Idioma: Español
Referencias bibliográficas: 44
Paginas: 339-343
Archivo PDF: 362.37 Kb.


RESUMEN

El infarto agudo del Miocardio (IAM) es una necrosis irreversible del músculo cardiaco secundario a una isquemia prolongada debido a un desbalance entre el aporte y la demanda del oxígeno. De acuerdo a la Organización Mundial de la Salud, las enfermedades cardiovasculares causan 16.7 millones de muertes alrededor del mundo. En nuestro país para el año 2004 la primera causa de muerte fue el infarto agudo de miocardio. Debido a esto, se comparo el clopidogrel con la aspirina como fármacos utilizados en la prevención secundaria. Se analizaron estudios que compararan ambos fármacos en su relación riesgo beneficio y costo-beneficio. Se encontró que ambos fármacos son útiles en la prevención de la enfermedad, la diferencia fue la disminución de complicaciones y rehospitalización en los pacientes tratados con clopidogrel. Llegando concluir que para la escogencia del tratamiento es necesario clasificar al paciente de acuerdo a sus factores de riesgo ya que, la diferencia de costos entre ambos fármacos es significativa, por lo que la aspirina continúa siendo el tratamiento de base utilizado.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk ofischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329-1339.

  2. American Heart Association. American Heart Association 2000 statistics.10 Feb 2000. Disponible en: http//www.americanheart.org

  3. Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. Circulation 1998;98:1860-8.

  4. Ault KA CA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF et al. Platelet activation in patients after an acute coronary syndrome. J Am Coll Cardiol 1999; 33: 634-639.

  5. Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206-18.

  6. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell’Angina Instabile Group. Circulation. 1990;82:17-26.

  7. Bennett, CL, Connors, JM, Carwile, JM, Moake, JL, Bell, WR, Tarantolo, SR, McCarthy, LJ, Sarode, R, Hatfield, AJ, Feldman, MD, Davidson, CJ, Tsai, HM, & Michalets, EL: Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000, 342:17731777.

  8. Califf RM. Acute ischemic syndromes Med Clin of NA 1995, 79(5): 999-1203.

  9. Cannon CP. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarctation in patients with symptomatic atherothrombosis (CAPRIE trial). The American College of Cardiology. 2002 Oct 1; 90(7).

  10. Clopidogrel bisulfate. Mosby’s drug consult. 2004.

  11. Crane VS. Formulary and economic considerations in the selection of antiplatelet agents. Am J Health Syst Pharm 1998;55:S28-31.

  12. Deepak L, Bhatt, Hirsch A.T, Ringleb P.A, Hacke W, Topol E.J. Reduction in the Need for Hospitalization for Recurrent Ischemic Events and Bleeding With Clopidogrel Instead of Aspirin. Am Heart J. 2000; 140(1):67-73

  13. Ferguson III JJ, Gonzalez ER, Kannel WB, et al. Clinical safety and efficacy of clopidogrel—implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease. Clin Ther 1998;20:B42-53.

  14. Furry B. Acute Coronary Syndromes. Conference Coverage. American College of Cardiovascular Nursing. Jun 2000.

  15. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992;326:242-250.

  16. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost-effectiveness of aspirin, clopidogrel or both for secondary prevention of coronary heart disease. N Engl J Med 2002;346:1819-21.

  17. Gaspoz JM, Moerloose O. Aspirin or clopidogrel for secundary prevention of cardiovascular events: is there a winner?. Am J Med. 2004 Jun 15; 116(12).

  18. Gent M, Blakeley JA, Easton JB: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-1220.

  19. Gorelick PB, Born GVR, D’Agostino RB, et al. Therapeutic benefitaspirin revisited in light of the introduction of clopidogrel. Stroke 1999;30:1716-21.

  20. Hamberg M, Svensson J, Samuelsson B: Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci 1995; 72:2994.

  21. Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 2000;31:1779-84.

  22. Hankey, GJ: Clopidogrel and thrombotic thrombocytopenic purpura. Lancet 2000, 356:269270.

  23. Hass WK, Easton JD, Adams JP, Pryse Philips W, Molony BA, Anderson S, A randomized trial comparing ticlopidine hidrochloride with aspirin for the prevention of stroke in high-risk patients. New Eng J Med 1990; 321: 501-507.

  24. Hirsh J, Dalen JE, Fuster V, Harker L, Patrono C, Roth GJ. Aspirin and other platelet-active drugs: the relationship between dose, effectiveness, and sideeffects. Chest 1995; 108:S247-57.

  25. Jaffe EA, Weksler BB: Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J Clin Invest 1991; 63:532.

  26. Lands WEM, Samuelsson B: Phospholipid precursors of prostaglandins. Biochim Biophys Acta 1991; 164:426

  27. Lau W.C., Gurbel P.A., Watkins P.B., et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109:166-71.

  28. Marcus AJ. Platelets and their disorders. En: Ratnoff OD, Forbes CD, ed. Disorders of Hemostasis. (3rd ed). Philadelphia: WB Saunders, 1996: 79-137.

  29. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]. Circulation 1998;97:1702-7.

  30. Mills DC, Purir, Minniti C, Grana G, Freedman MD, ET AL: Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992; 124: 430-436.

  31. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1995; 72: 1.177-1.184.

  32. Pollack CV. Utility of platelet ADP receptor antagonism in the emergency department: a review. J Emerg Med 2003;24:45-54.

  33. Povéda J, Sáenz ME. Síndromes Coronarios Agudos: evaluación y manejo. Acta méd. Costarric vol.42 no.3 San José Sept. 2000

  34. Principales Causas de Muerte [base de datos en Internet]. CR: Instituto Nacional de Estadísticas y Sensos. c2004. Disponible en: http://www.inec.go.cr

  35. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667-72.

  36. Sarasin F.P., Gaspoz J.M., Bounameaux H.. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch Intern Med 2000;160:2773-8.

  37. Schleinitz M.D., Weiss J.P., Owens D.K.. Clopidogrel versus aspirin for secondary prophylaxis of vascular events. Am J Med 2004;116:797-806.

  38. Schror K. The basic pharmacology of ticlopidine and clopidogrel. Platelets 1993; 4:252-61.

  39. Shimbo D, Pickering T, Phil D. Platelets in cardiovascular and non cardiovascular disorders: pathophysiology, pharmacology and terapeutics. Cardiovasc Rev Rep 2004; 25(1):18-24.

  40. Storey R.F., Newby L.J., Heptinstall S.. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001;12:443-7.

  41. Takahashi O: Characteristics of rat platelets and relative contributions of platelets and blood coagulation to hemostasis. Food Chem Toxicol 2000; 38: 203-218.

  42. Van Belle E, Lablanche JM, Bauters C, Renaud N, McFadden EP, Bertrand ME. Coronary angioscopic findings in the infarctrelated vessel within 1 month of acute myocardial infarction. Circulation 1998; 97: 26-33.

  43. World Health Report: Changing History. Geneva, Switzerland: World Health Organization, 2004. Disponible en: http://www.who.int/whr/2004/annex/topic/en/annex_2_en.pdf

  44. Yeghiazarians Y, et al. Unstable angina pectoris. N Engl J Med 2000:342(2),101-114.




2020     |     www.medigraphic.com